Q-omics provides the consensus-scored SLC23A4P profile across patient tissues and cancer cell-line models. SLC23A4P expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SLC23A4P is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, SLC23A4P RNA expression shows 6,882 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight HNSC, KIRC, and STAD as cancer lineages where SLC23A4P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC23A4P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC23A4P survival associations across molecular data types. SLC23A4P RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC23A4P RNA expression–survival associations across cancer types. High SLC23A4P expression shows unfavorable associations in COAD and READ, but favorable associations in HNSC, KIRC, KIRP and MESO. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SLC23A4P RNA expression.
This table summarizes SLC23A4P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SLC23A4P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC23A4P shows lower tumor expression in KICH and higher tumor expression in KIRC, HNSC, KIRP, LUSC and PAAD. The KIRC box plot shows higher SLC23A4P RNA expression in tumor versus normal tissue (log2 FC = +2.009, t-test p < 0.001).
This table shows molecular features associated with SLC23A4P in patient tissues and cancer cell lines. In patient samples, SLC23A4P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
